Title:Pharmacogenomics and Toxicogenomics in Personalized Public Health: Integrating Genetic Insights, Emerging Technologies, and Global Regulatory Perspectives to Prevent Drug-induced Toxicity and Enhance Therapeutic Outcomes
Volume: 23
Author(s): Ugwu Okechukwu Paul-Chima*
Affiliation:
- Department of Research, Publication, and Extension, Kampala International University, Kampala, Uganda
Keywords:
Pharmacogenomics, toxicogenomics, personalized medicine, pharmacovigilance, computational modeling, gene-editing technologies.
Abstract:
Introduction: Patient drug response, therapeutic outcomes, and the prevention
of adverse reactions rely on pharmacogenomics and toxicogenomics, which study genetic
variations influencing drug metabolism and toxicity. Integrating pharmacogenomics with
toxicogenomics enhances patient safety by identifying individuals at risk of drug-induced
toxicity and enables clinicians to make precise dose adjustments.
Objectives: This research explores the implementation of pharmacogenomics and toxicogenomics
in personalized medicine to assess their safety benefits, improvements in disease
treatment, and potential to reduce healthcare costs. It also evaluates emerging technologies
and discusses challenges associated with deploying these methodologies.
Methods: A comprehensive analysis of genetic studies involving drug-metabolizing enzymes,
receptors, and transport proteins was conducted. The evaluation focused on biomedical
technologies, bioinformatics, and computational modeling to determine their
ability to detect genomic indicators of drug toxicity. Additionally, this study examined
how artificial intelligence (AI), machine learning (ML), and gene-editing technologies
contribute to the advancement of personalized medical treatments.
Results and Discussion: Technological advancements have facilitated the discovery of
genomic markers, improving drug toxicity prediction, regulatory assessment, and public
health strategies. Integrating pharmacogenomic and toxicogenomic data into electronic
medical records supports enhanced clinical decision-making and strengthens drug safety
monitoring. However, widespread adoption remains limited due to ongoing ethical concerns,
accessibility barriers, and regulatory inconsistencies.
Conclusion: Collaboration among researchers, clinicians, industry stakeholders, and policymakers
is essential to overcome implementation barriers to pharmacogenomic integration.
The successful incorporation of pharmacogenomic and toxicogenomic data depends
on expanding research foundations, enacting policy reforms, and developing educational
initiatives to enhance patient safety and global healthcare outcomes.
